What Is Spatial Immunology?
July 23, 2026Core Framework & Diagram What Is the Tumor Immune Atlas?
July 23, 2026
What Is the Tumor Immune Atlas?
Every tumor has its own immune 'fingerprint' — reading it is the prerequisite for truly precise attacks
By the Editors 1-min read
Why does the same 'lung cancer,' with some patients having astonishing effects from immunotherapy while others don't respond at all? Why does the same immune cell infiltration have completely different predictive significance in different tumors?
Over the past twenty years, cancer research has accumulated massive amounts of genome, transcriptome, proteome, and immune cell data — but these data are mostly scattered across different studies, lacking systematic integration.
The Tumor Immune Atlas systematically integrates this scattered data, drawing a complete 'immune landscape map' for each major cancer type — what immune cells are in this cancer, what their state is, how they interact with tumor cells, what immune characteristics correlate with prognosis and treatment response.
This map is the strategic reference manual for individualized immunotherapy.
KEY TAKEAWAYS
01
The Tumor Immune Atlas systematically integrates multi-omics data, drawing complete 'immune landscape maps' for different cancer types — the strategic reference manual for individualized immunotherapy.
02
TCGA (11,000 cases, 33 cancer types) is the data foundation; Thorsson et al.'s 2018 pan-cancer analysis divided tumors into six immune subtypes (C1-C6), from 'inflammatory hot' to 'immune desert.'
03
CIBERSORT/TIMER deconvolution tools can estimate immune cell composition from existing bulk RNA-seq data; TIMER2.0 lets anyone query tumor immune infiltration data online.
04
NK cell infiltration in multiple cancers correlates with better prognosis; NK cell absence in 'cold tumors' provides biological rationale for NK cell therapy as a complement when T cell approaches fail.
05
Six immune subtypes correspond to different treatment strategies: C2 responds best to checkpoint inhibitors, C5 needs 'warming up' first then immunotherapy, C1/C6 may respond better to antiangiogenic or TGF-β targeting.
06
Future direction: dynamic longitudinal atlas (continuous liquid biopsy sampling) + AI real-time recommendations + single-cell/spatial technology integration — upgrading 'static maps' to 'real-time navigation.'
Art 135
What Is Immune Microenvironment Engineering?
→
Art 136
What Is Immune Nanotechnology?
→
